Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)
Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)
In the ADDITION-MCI project, patients with a diagnosis of mild cognitive impairment probably caused by Alzheimer's disease will receive plasma exchange.
Repeated plasma exchanges will be conducted, and cognitive outcomes will be measured before and after the intervention.
Inclusion Criteria:
Clinical diagnosis of Alzheimer's Disease
MoCA score < 27 and >17
Able to give informed consent as judged by the doctor setting the AD diagnosis and study doctor.
At least one biomarker of the AT(N)-classification system supporting the diagnosis
Expected to live more than five years at inclusion by the study doctor.
Exclusion Criteria:
Known IgA deficiency
Known severe protein S depletion
Previous severe allergic reaction after transfusion of a blood product
Known heart failure
Known liver failure
Known kidney failure
Previous cancer <10 years.
Not deemed able to participate by the study staff
Other severe chronic diseases, interfering with the TPE-procedure
Ongoing infections
Other unresolved medical conditions
Known coagulopathies
Fulfilling ICD-10 criteria for dementia at baseline, as evaluated by the evaluating physician.
Peripheral veins not expected to be suitable for repeated venous access procedures.